Apogee Therapeutics Inc’s recently made public that its Chief Medical Officer Dambkowski Carl unloaded Company’s shares for reported $48463.0 on Mar 05 ’25. In the deal valued at $30.48 per share,1,590 shares were sold. As a result of this transaction, Dambkowski Carl now holds 251,033 shares worth roughly $9.75 million.
Then, HENDERSON MICHAEL THOMAS sold 10,000 shares, generating $301,511 in total proceeds. Upon selling the shares at $30.15, the Chief Executive Officer now owns 1,292,987 shares.
Before that, HENDERSON MICHAEL THOMAS bought 10,000 shares. Apogee Therapeutics Inc shares valued at $301,501 were divested by the Officer at a price of $30.15 per share.
Citigroup initiated its Apogee Therapeutics Inc [APGE] rating to a Buy in a research note published on March 13, 2025; the price target was $95. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in late November with a ‘”a Buy”‘ rating. BofA Securities began covering APGE with “Buy” recommendation on May 10, 2024. BTIG Research started covering the stock on December 20, 2023. It rated APGE as “a Buy”.
Price Performance Review of APGE
On Tuesday, Apogee Therapeutics Inc [NASDAQ:APGE] saw its stock fall -3.77% to $38.83. Over the last five days, the stock has lost -3.58%. Apogee Therapeutics Inc shares have fallen nearly -14.28% since the year began. Nevertheless, the stocks have fallen -40.44% over the past one year. While a 52-week high of $71.75 was reached on 01/07/25, a 52-week low of $29.10 was recorded on 03/04/25. SMA at 50 days reached $38.30, while 200 days put it at $45.82.
Levels Of Support And Resistance For APGE Stock
The 24-hour chart illustrates a support level at 37.46, which if violated will result in even more drops to 36.09. On the upside, there is a resistance level at 40.10. A further resistance level may holdings at 41.36. The Relative Strength Index (RSI) on the 14-day chart is 55.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.95, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 23.81%. Stochastics %K at 83.06% indicates the stock is a selling.
How much short interest is there in Apogee Therapeutics Inc?
A steep rise in short interest was recorded in Apogee Therapeutics Inc stocks on 2025-02-28, dropping by -1.07 million shares to a total of 7.76 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 8.83 million shares. There was a decline of -13.76%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 08, 2023 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $40 price target.
